Programme death ligand 1 expressions as a surrogate for determining immunotherapy in cervical carcinoma patients
<h4>Background</h4> The programme death ligand1 and its receptor (PD-1/PD-L1) interaction is a target for blockage by immunotherapy that uses the body’s own immune system. Some studies show that PD-L1 expressing tumours are also more aggressive with poor prognosis. This study evaluated t...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2022-01-01
|
| Series: | PLoS ONE |
| Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8827435/?tool=EBI |